Absence of an interaction between artesunate and atovaquone-proguanil

European Journal of Clinical Pharmacology

Volumn 55, Issue 6, 1999, Pages 469-474

  Van Vugt, M ^a,b   Edstein, M D ^d   Proux, S ^a   Lay, K ^a   Ooh, M ^a   Looareesuwan, S ^c   White, N J ^a,c,e   Nosten, F ^a,e  

^a SHOKLO MALARIA RESEARCH UNIT   (Thailand)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c MAHIDOL UNIVERSITY   (Thailand)

^d AUSTRALIAN ARMY MALARIA INSTITUTE   (Australia)

^e JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

Artesunate; Atovaquone; Proguanil

Indexed keywords

ARTESUNATE; ATOVAQUONE; ATOVAQUONE PLUS PROGUANIL; PROGUANIL;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDICATION; DRUG MIXTURE; DRUG TOLERABILITY; DRUG TRANSFORMATION; FEMALE; HUMAN; HUMAN EXPERIMENT; MALARIA; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THAILAND;

ADULT; ANTIMALARIALS; ARTEMISININS; ATOVAQUONE; CHLOROGUANIDE; DRUG COMBINATIONS; DRUG INTERACTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; NAPHTHOQUINONES; SESQUITERPENES; TIME FACTORS;

EID: 0032796920     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050658     Document Type: Article

References (21)

1. White NJ (1992) Antimalarial drug resistance: the pace quickens. J Antimicrob Chemother 30: 571-585
2. Price RN, Nosten F, Luxemburger C, van Vugt M, Phaipun L, Chongsuphajaisiddhi T, White NJ (1997) Artesunate/mefloquine treatment of multi-drug resistant falciparum malaria. Trans R Soc Trop Med Hyg 91: 574-577
3. van Vugt M, Brockman A, Gemperli B, Luxemburger C, Gathmann I, Royce C, Slight T, Looareesuwan S, White NJ, Nosten F (1998) Randomized comparison of artemether-benflumetol and artesunate-mefloquine in the treatment of multidrug resistant falciparum malaria. Antimicrob Agents Chemother 42: 135-139
4. White NJ (1997) Assessment of the pharmacodynamic properties of the antimalarial drugs in vivo. Antimicrob Agents Chemother 41: 1413-1422
5. Price RN, Nosten F, Luxemburger C, ter Kuile FO, Phaipun L, Chongsuphajaisiddhi T, White NJ (1996) Effects of artemisinin derivatives on malaria transmissibility. Lancet 347: 1654-1658
6. Looareesuwan S, Viravan C, Webster HK, Kyle DE, Hutchinson DB, Canfield CJ (1996) Clinical studies of atovaquone, alone or in combination with other antimalarial drugs, for treatment of acute uncomplicated malaria in Thailand. Am J Trop Med Hyg 54: 62-66
7. White NJ (1998) Preventing antimalarial drug resistance through combinations. Drug Resistance Updates 1: 3-9
8. Rolan PE, Mercer AJ, Weatherley BC, Holdich T, Meire H, Peck RW, Ridout G, Posner J (1994) Examination of some factors responsible for a food-induced increase in absorption of atovaquone. Br J Clin Pharmacol 37: 13-20
9. Shanks GD, Edstein MD, Chedester AL, Smith CD, Corcoran KD, Ngampochjana M, Hansukjariya P, Sattabongkot J, Webster HK (1994) Proguanil plus sulfamethoxazole is not causally prophylactic in the Macaca mulatta-Plasmodium cynomolgi model. Am J Trop Med Hyg 50: 641-645
10. Ward SA, Watkins WM, Mberu E, Saunders JE, Koech DK, Gilles HM, Howells RE, Breckenridge AM (1989) Inter-subject variability in the metabolism of proguanil to the active metabolite cycloguanil in man. Br J Clin Pharmacol 27: 781-787
11. Hussein Z, Eaves J, Hutchinson DB, Canfield CJ (1997) Population pharmacokinetics of atovaquone in patients with acute malaria caused by Plasmodium falciparum. Clin Pharmacol Ther 61: 518-530
12. Sabchareon A, Attanath P, Phanuaksook P, Chanthavanich P, Poonpanich Y, Mookmanee D, Chongsuphajaisiddhi T, Sadler BM, Hussein Z, Canfield CJ, Hutchinson DBA (1998) Efficacy and pharmacokinetics of atovaquone and proguanil in children with multidrug-resistant Plasmodium falciparum malaria. Trans R Soc Trop Med Hyg 92: 201-206
13. Hudson AT, Dickins M, Ginger CD, Gutteridge WE, Holdich T, Hutchinson DBA, Pudney M, Randall AW, Latter VS (1991) 566C80: a potent broad spectrum anti-infective agent with activity against malaria and opportunistic infections in AIDS. Drugs Exp Clin Res XVII: 427-435
14. Hughes WT, Kennedy W, Shenep JL, Flynn PM, Hetherington SV, Fullen G, Lancaster DJ, Stein DS, Palte S, Rosenbaum D, Liao SHT, Blum MR, Rogers MD (1991) Safety and pharmacokinetics of 566C80, a hydroxynaphthaquinone with anti-Pneumocystis carinii activity: a phase II study in human immunodeficiency virus (HIV) - Infected men. J Infect Dis 163: 843-848
15. Wattanagoon Y, Taylor RB, Moody RR, Ochekpe NA, Looareesuwan S, White NJ (1987) Single dose pharmacokinetics of proguanil and its metabolites in healthy subjects. Br J Clin Pharmacol 24: 775-780
16. Helsby NA, Ward SA, Edwards G, Howells RE, Breckenridge AM (1990) The pharmacokinetics and activation of proguanil in man: consequences of variability in drug metabolism. Br J Clin Pharmacol 30: 593-598
17. Ashton M, Duy Sy N, Van Huong N, Gordi T, Ngoc Hai T, Xuan Huong D, Thi Nieu N, Dinh Cong L (1998) Artemisinin kinetics and dynamics during oral and rectal treatment of uncomplicated malaria. Clin Pharmacol Ther 63: 482-493
18. Tan-ariya P, Na-Bangchang K, Ubalee R, Thanavibul A, Thipawangkosol P, Karbwang J (1998) Pharmacokinetic interactions of artemether and pyrimethamine in healthy male Thais. Southeast Asian J Trop Med Public Health 29: 18-23
19. Batty KT, Davis TME, Thu LTA, Binh TQ, Anh TK, Ilett KF (1996) Selective high-performance liquid Chromatographic determinations of artesunate and α-and β-dihydroartemisinin in patients with falciparum malaria. J Chromatogr 677: 345-350
20. Edwards G (1994) Measurement of artemisinin and its derivatives in biological fluids. Trans R Soc Trop Med Hyg 88: 37-39
21. Li WH, Shu HL, Xu GY, Zeng YL (1982) The binding of qinghaosu (artemisinine) and its derivatives to plasma protein. Acta Pharm Sin 17: 783-786